These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 3257237)
1. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins. Trenn G; Pettit GR; Takayama H; Hu-Li J; Sitkovsky MV J Immunol; 1988 Jan; 140(2):433-9. PubMed ID: 3257237 [TBL] [Abstract][Full Text] [Related]
2. Precursor frequency analysis of bryostatin activated lymphocytes. Fleming MD; Barrett SK; Bear HD J Surg Res; 1994 Jul; 57(1):74-9. PubMed ID: 8041153 [TBL] [Abstract][Full Text] [Related]
3. Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells. Do Y; Hegde VL; Nagarkatti PS; Nagarkatti M Cancer Res; 2004 Sep; 64(18):6756-65. PubMed ID: 15374994 [TBL] [Abstract][Full Text] [Related]
4. gamma-Interferon plays a key role in T-cell-induced tumor regression. Tuttle TM; McCrady CW; Inge TH; Salour M; Bear HD Cancer Res; 1993 Feb; 53(4):833-9. PubMed ID: 8428364 [TBL] [Abstract][Full Text] [Related]
5. Successful treatment of murine melanoma with bryostatin 1. Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785 [TBL] [Abstract][Full Text] [Related]
6. Highly lytic in vivo primed cytolytic T lymphocytes devoid of lytic granules and BLT-esterase activity acquire these constituents in the presence of T cell growth factors upon blast transformation in vitro. Berke G; Rosen D J Immunol; 1988 Sep; 141(5):1429-36. PubMed ID: 3261748 [TBL] [Abstract][Full Text] [Related]
7. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level. Sensi M; Orosz CG; Bach FH J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778 [TBL] [Abstract][Full Text] [Related]
8. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes. Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898 [TBL] [Abstract][Full Text] [Related]
9. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423 [TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase I is enriched in granules of in vitro- and in vivo-activated cytotoxic T lymphocytes. Brown GR; McGuire MJ; Thiele DL J Immunol; 1993 Jun; 150(11):4733-42. PubMed ID: 8496587 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of novel protein kinase C delta in BL6 murine melanoma cells inhibits the proliferative capacity in vitro but enhances the metastatic potential in vivo. La Porta CA; Di Dio A; Porro D; Comolli R Melanoma Res; 2000 Apr; 10(2):93-102. PubMed ID: 10803709 [TBL] [Abstract][Full Text] [Related]
12. Studies on the induction and expression of T cell-mediated immunity. XIV. Antigen-nonspecific oxidation-dependent cellular cytotoxicity (ODCC) mediated by sodium periodate oxidation of cytotoxic T lymphocytes. Fan J; Bonavida B J Immunol; 1983 Sep; 131(3):1426-32. PubMed ID: 6193189 [TBL] [Abstract][Full Text] [Related]
13. Bryostatin/ionomycin-activated T cells mediate regression of established tumors. Chin CS; Graham LJ; Hamad GG; George KR; Bear HD J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126 [TBL] [Abstract][Full Text] [Related]
14. Posttranslational regulation of Lck and a p36-38 protein by activators of protein kinase C: differential effects of the tumor promoter, PMA, and the non-tumor-promoter, bryostatin. Galron D; Ansotegui IJ; Isakov N Cell Immunol; 1997 Jun; 178(2):141-51. PubMed ID: 9225005 [TBL] [Abstract][Full Text] [Related]
16. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857 [TBL] [Abstract][Full Text] [Related]
17. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. Kataoka T; Shinohara N; Takayama H; Takaku K; Kondo S; Yonehara S; Nagai K J Immunol; 1996 May; 156(10):3678-86. PubMed ID: 8621902 [TBL] [Abstract][Full Text] [Related]
18. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. Nagata Y; Furugen R; Hiasa A; Ikeda H; Ohta N; Furukawa K; Nakamura H; Furukawa K; Kanematsu T; Shiku H J Immunol; 1997 Aug; 159(3):1336-43. PubMed ID: 9233630 [TBL] [Abstract][Full Text] [Related]
19. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent. Wild J; Grusby MJ; Schirmbeck R; Reimann J J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922 [TBL] [Abstract][Full Text] [Related]
20. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis. Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]